WESTLAKE VILLAGE, Calif., Feb. 4, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the 2015 Leerink Global Healthcare Conference.
|Event:||2015 Leerink Global Healthcare Conference|
|Date:||Wednesday, February 11, 2015|
|Time:||10:40 a.m. ET|
A live webcast will be available under the Investors section of the Company's website at www.kytherabiopharma.com. The presentation will be archived on the website and will be available for at least 14 days.
KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. KYTHERA's product candidate, ATX-101, is currently in late-stage clinical development for the reduction of submental fat, which commonly presents as a double chin, and is a potential first-in-class submental contouring injectable drug. The Dermatology and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review KYTHERA's New Drug Application (NDA) for ATX-101 (deoxycholic acid) for "improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults" on March 9, 2015. The FDA has determined the NDA will have a Prescription Drug User Fee Act (PDUFA) action date of May 13, 2015. KYTHERA also maintains an active research interest in hair and fat biology, pigmentation modulation and facial contouring. Find more information at www.kytherabiopharma.com.
CONTACT: Investor Contact: Heather Rowe, Director, Investor Relations Tel: (818) 587- 4559 firstname.lastname@example.org
Source:KYTHERA Biopharmaceuticals, Inc.